Blogs
Healthcare and Medtech Research Reports
Jun 08, 2026
Summary HR+/HER2- breast cancer continues to represent a major target indication for SERDs, with approximately 481,000 cases reported in 2024 in the 7MM. High-profile failures from Sanofi (amcenestrant) and a long list of early-stage candidates such as GDC-029, AZD9496, GDC-0927, ZnC5, LSZ-102, brinale...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper